Table 3.
STK11 co-alterations and outcomes across all tumor types and therapies
|
STK11 alterations across all tumor types N=60, 1.7%) |
Median PFS from any first therapy* (95% CI) (months) univariate |
HR (95% CI) univariate |
P value univariate |
HR (95% CI)) Multivariate ** |
P value multivariate |
|---|---|---|---|---|---|
| STK11 and KRAS co-altered N=27/60 (45%) | 3 (1.3-4.7) | 3.1 (1.7-5.7) | <0.0005 | 2.3 (1-5.3) | 0.06 |
| STK11 altered with KRAS wild-type N= 33/60 (55%) (reference) | 10 (4.9-15.7) | ||||
| STK11 and TP53 co-altered N=29/60(48%) | 4.3 (0-10.8) | 1.3 (0.8-2.3) | 0.3 | ||
| STK11 altered with TP53 wild type=31/60 (52%) (reference) | 7.1 (2.3-11.9) | ||||
| STK11 and TP53 and KRAS co-altered N=15/60 (25%) | 1.9 (1.3-2.5) | 3.6 (1.9-6.7) | <0.0005 | 2 (0.9-4.4) | 0.08 |
| STK11 altered with either TP53 or KRAS or both wild type N=45/60 (75%) (reference) | 8.9 (5.1-12.7) | ||||
| STK11 altered with both KRAS and TP53 wild-type N=19/60 (32%) | 9.6 (5.1-14.2) | 0.6 (0.3-1) | 0.06 | 0.5 (0.2-1.4) | 0.9 |
| STK11 altered with KRAS or TP53 alteration N=41//60 (68%) (reference) | 4.6 (1.6-7.6) | ||||
| STK11 altered and KRAS co-altered lung cancers N=16/27 (59%) | 3 (1-5) | 1.7 (0.7-3.9) | 0.2 | 1.8 (0.5-6.1) | 0.3 |
| STK11 altered with KRAS wild type lung cancers N=11/27(41%) (reference) | 6.8 (3.5-10.2) | ||||
| STK11, KRAS, and TP53 co-altered lung cancers N=7/27 (26%) | 1.6 (1.1-2.1) | 2.8 (1.1-6.9) | 0.02 | 1 (0.2-5.7) | 0.9 |
| STK11 altered with either KRAS or TP53 or both wild type lung cancers N=20/27 (74%) (reference) | 5.9 (3.7-8.1) | ||||
| STK11 alteration only lung cancer N=6/27 (22%) | 7.1 (0.3-13.9) | 0.4 (0.1-1.2) | 0.09 | 0.997 (.2-5.7) | 0.9 |
| STK11 altered with KRAS, or TP53 alteration lung cancer N=21/27 (78%) (reference) | 4 (1.6-6.4) | ||||
| STK11 and TP53 co-altered lung cancers N=15/27 (56%) | 1.9 (1.2-2.6) | 2.3 (1.0-25.2) | 0.04 | 2.4 (0.6-9.3) | 0.2 |
| STK11 altered with TP53 wild type lung cancers N=12/27 (44%) (reference) | 6.5 (3.3-9.7) | ||||
| Median OS from any first therapy (95% CI) (months) univariate |
HR (95% CI) univariate |
P value univariate |
HR (95% CI)) multivariate |
P value multivariate |
|
| STK11 and KRAS co-altered N=27/60 (45%) | 16.2 (12.5-20) | 2.8 (1.5-5.4) | 0.001 | 2.9 (1.2-7.2) | 0.02 |
| STK11 altered with KRAS wild-type N= 33/60 (55%) (reference) | 26.3 (0-77.3) | ||||
| STK11 and TP53 co-altered N=29/60 (48%) | 16.2 (15.2-17.2) | 1.6 (0.9-3.1) | 0.1 | 1.7 (0.8-3.9) | 0.2 |
| STK11 altered with TP53 wild type, N=31/60 (52%) (reference) | 21.2 (13.8-28.6) | ||||
| STK11 and TP53 and KRAS co-altered N=15/60 (25%) | 11.9 (3.8-20) | 2.8 (1.5-5.5) | 0.001 | 1.2 (0.3-4.2) | 0.8 |
| STK11 altered with either TP53 or KRAS or both wild type N=45/60 (75%) (reference) | 21.2 (12.3-39) | ||||
| STK11 altered without KRAS or TP53 alteration N=19//60 (32%) | 25.1 (11-19.4) | 0.4 (0.2-0.9) | 0.02 | 0.85 (0.2-3.1) | 0.8 |
| STK11 altered with KRAS or TP53 alteration N=41//60 (68%) (reference) | 18.1 (16.2-23.1) | ||||
| STK11 altered and KRAS co-altered lung cancers N=16/27 (59%) | 18 (4.4-31.7)) | 0.5 (0.2-1.3) | 0.1 | 0.4 (0.1-1.7) | 0.2 |
| STK11 altered with KRAS wild type lung cancers N=11/27(41%) (reference) | 17.8 (11.6-32.2) | ||||
| STK11, KRAS, and TP53 co-altered lung cancers 7/27(26%) | 9.2 (5.9-12.5) | 2.2 (0.8-5.9) | 0.1 | 1.6 (0.2-13) | 0.7 |
| STK11 altered with either KRAS or TP53 or both wild type lung cancers 20/27(74%) (reference) | 20.5 (15.1-26) | ||||
| STK11 altered and TP53 co-altered lung cancers 15/27 (56%) | 11.9 (1.7-22.1) | 1.8 (0.7-4.6) | 0.2 | 2.6 (.4-15.7) | 0.3 |
| STK11 altered with TP53 wild type lung cancers 12/27 (44%) (reference) | 21.2 (16.8-25.6) |
*
Median PFS and OS is from any first therapy started after diagnosis. STK11 and KRAS co-altered patients 6/27 (22%) received immunotherapy; 18/27 (67%), cytotoxic and antiangiogenic therapy, 3/27 (11%), supportive care.
STK11 and KRAS co-altered lung cancers (16/27), 3/16(19%) received immunotherapy; 10/16(63%), cytotoxic therapy; and 3/16 (19%), supportive care.
Of the STK11-altered KRAS wild type cancers, 6/33 (18%) received immunotherapy; 21/33(64%), cytotoxic therapy; 6 /33 (18%) received other therapies.
**
Variables with p value <0.25 for association with PFS and OS were included in the multivariate analysis